In conclusion, based on the current data, the TH regimen has a low relapse risk and improved overall survival in early-stage node-negative, HER2-positive breast cancer, alongside being cost-effective compared to regimens like ACTH and TCH. The gene discussed is POMC; the disease is breast cancer.